Dementia is a syndrome which has deterioration in memory, thinking, behaviour and ability to perform everyday activities.
Dementia mainly affects older people, but it is not a normal condition of aging.
Worldwide, there are 47.5 million people with dementia, and each year there are 7.7 million new cases of the disease.
Alzheimer's disease is the most common cause of dementia – it accounts for 60-70% of all cases.
Dementia is one of the major causes of disability and dependency among older people worldwide.
Dementia has physical, psychological, social and economic impact on caregivers, family and society.
The testimony of the drug
Reminyl is indicated for the treatment of dementia of Alzheimer's type mild or moderate degree, including (in particular) with chronic disorders of cerebral circulation.
hypersensitivity to galantamine hydrobromide
patients with severe impairment of renal function (Cl creatinine less than 9 ml/min) due to lack of data on the application;
severe violations of liver function.
Application of pregnancy and breastfeeding
Research of the drug in pregnant women have not been conducted.
Reminyl may used during pregnancy only if the potential benefit to them outweighs the potential risk to the fetus.
Method of application and doses
Inside, 1 time a day (morning), preferably with a meal.
Initial dose. The recommended starting dose is 8 mg/day.